CORT News and Press, Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT PR Newswire LOS ANGELES , Feb. 27, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Corcept Therape...

NEW YORK, NY - February 26, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of all persons or entities that purc...

The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated th...

2026-02-24 19:48:52 ET More on Corcept Therapeutics Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not Why Corcept Therapeutics' Relacorilant Fell Short And What ...

2026-02-24 19:47:53 ET Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call February 24, 2026 5:00 PM EST... Read the full article on Seeking Alpha For further details see: Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript

2026-02-24 16:26:10 ET More on Corcept Therapeutics Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company Corcept: Korlym Defies Generics As Relacorilant H...

2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage co...

NEW YORK, NY - February 24, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of all persons or entities that purc...

NEW YORK, NY - February 24, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT T...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...